- Home
- AENT vs AQST Comparison
AENT vs AQST Comparison
Compare AENT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- AQST
- Stock Information
- Founded
- AENT 1990
- AQST 2004
- Country
- AENT United States
- AQST United States
- Employees
- AENT N/A
- AQST N/A
- Industry
- AENT Durable Goods
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- AQST Health Care
- Exchange
- AENT Nasdaq
- AQST Nasdaq
- Market Cap
- AENT 148.0M
- AQST 254.1M
- IPO Year
- AENT N/A
- AQST 2018
- Fundamental
- Price
- AENT $2.40
- AQST $2.76
- Analyst Decision
- AENT
- AQST Strong Buy
- Analyst Count
- AENT 0
- AQST 5
- Target Price
- AENT N/A
- AQST $11.40
- AVG Volume (30 Days)
- AENT 39.4K
- AQST 984.2K
- Earning Date
- AENT 05-12-2025
- AQST 05-12-2025
- Dividend Yield
- AENT N/A
- AQST N/A
- EPS Growth
- AENT N/A
- AQST N/A
- EPS
- AENT 0.13
- AQST N/A
- Revenue
- AENT $1,070,804,000.00
- AQST $57,561,000.00
- Revenue This Year
- AENT $4.77
- AQST N/A
- Revenue Next Year
- AENT N/A
- AQST $39.51
- P/E Ratio
- AENT $17.32
- AQST N/A
- Revenue Growth
- AENT N/A
- AQST 13.79
- 52 Week Low
- AENT $1.10
- AQST $2.20
- 52 Week High
- AENT $11.57
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- AENT 37.62
- AQST 48.51
- Support Level
- AENT $2.31
- AQST $2.65
- Resistance Level
- AENT $2.67
- AQST $3.05
- Average True Range (ATR)
- AENT 0.32
- AQST 0.16
- MACD
- AENT -0.02
- AQST 0.00
- Stochastic Oscillator
- AENT 16.02
- AQST 50.51
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.